Literature DB >> 27725637

Prostate cancer: Targeting apoptosis resistance in CRPC.

Clemens Thoma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27725637     DOI： 10.1038/nrurol.2016.200

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer.

Authors:  Iris Sze Ue Luk; Raunak Shrestha; Hui Xue; Yuwei Wang; Fang Zhang; Dong Lin; Anne Haegert; Rebecca Wu; Xin Dong; Colin C Collins; Amina Zoubeidi; Martin E Gleave; Peter W Gout; Yuzhuo Wang
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531
  1 in total
  3 in total

1.  Iso-pencillixanthone A from a marine-derived fungus reverses multidrug resistance in cervical cancer cells through down-regulating P-gp and re-activating apoptosis.

Authors:  Li Chen; Xinxin Li; Miaomiao Cheng; Siyuan Wang; Qiuhong Zheng; Qinying Liu
Journal:  RSC Adv       Date:  2018-12-10       Impact factor: 4.036

Review 2.  A Mini-Review of Flavone Isomers Apigenin and Genistein in Prostate Cancer Treatment.

Authors:  Xiaozhen Ji; Kai Liu; Qingyue Li; Qun Shen; Fangxuan Han; Qingmei Ye; Caijuan Zheng
Journal:  Front Pharmacol       Date:  2022-03-11       Impact factor: 5.810

3.  Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation.

Authors:  Hua Xu; Yin Sun; Chi-Ping Huang; Bosen You; Dingwei Ye; Chawnshang Chang
Journal:  Cancers (Basel)       Date:  2020-03-30       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.